Jian Wang

Jian Wang, PhD, MSRS, FCP, is Head of Global Regulatory Affairs (ex-China) at Hengrui, where he leads global regulatory strategy and supports the development and registration of innovative therapies worldwide. He previously held senior leadership roles across the pharmaceutical industry, including Global Head of Translational Science and Executive Director of Oncology Regulatory Science Strategy & Excellence at AstraZeneca. Prior to joining industry, Jian spent more than 13 years at the FDA’s Center for Drug Evaluation and Research (CDER), serving in the Office of New Drugs and the Office of Translational Sciences. 

During his tenure at the FDA, he led and contributed to key regulatory science and guidance initiatives in clinical trial design, surrogate endpoints, imaging biomarkers, clinical pharmacology, and model-informed drug development. Jian holds a PhD in Molecular Pharmacology and Clinical Pharmacogenomics and an MS in Regulatory Science from the University of Southern California. He serves as an Adjunct Associate Professor at the University of North Carolina at Chapel Hill and is a Fellow of the American College of Clinical Pharmacology (FCP).